| Full text | |
| Author(s): Show less - |
Ribeiro, Karina Braga
[1, 2]
;
Levi, Jose Eduardo
[3]
;
Pawlita, Michael
[4]
;
Koifman, Sergio
[5]
;
Matos, Elena
[6]
;
Eluf-Neto, Jose
[7]
;
Wunsch-Filho, Victor
[8]
;
Curado, Maria Paula
[1, 9]
;
Shangina, Oxana
[10]
;
Zaridze, David
[10]
;
Szeszenia-Dabrowska, Neonila
[11]
;
Lissowska, Jolanta
[12, 13]
;
Daudt, Alexander
[14]
;
Menezes, Ana
[15]
;
Bencko, Vladimir
[16, 17]
;
Mates, Dana
[18]
;
Fernandez, Leticia
[19]
;
Fabianova, Eleonora
[20]
;
Gheit, Tarik
[1]
;
Tommasino, Massimo
[1]
;
Boffetta, Paolo
[1, 21, 22]
;
Brennan, Paul
[1]
;
Waterboer, Tim
[4]
Total Authors: 23
|
| Affiliation: Show less - | [1] Int Agcy Res Canc, F-69008 Lyon - France
[2] Fac Ciencias Med Santa Casa Sao Paulo, Dept Social Med, Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst Trop Med, Virol Unit, Sao Paulo - Brazil
[4] German Canc Res Ctr, Infect & Canc Program, Heidelberg - Germany
[5] Fiocruz MS, Natl Sch Publ Hlth, BR-21045900 Rio De Janeiro - Brazil
[6] Univ Buenos Aires, Angel H Roffo Oncol Inst, Buenos Aires, DF - Argentina
[7] Univ Sao Paulo, Fac Med, Sao Paulo - Brazil
[8] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo - Brazil
[9] Associacao Combate Ao Canc Goias, Goiania, Go - Brazil
[10] NN Blokhin Canc Res Ctr, Dept Epidemiol & Prevent, Moscow - Russia
[11] Inst Occupat Med, Lodz - Poland
[12] Ctr Canc, Dept Epidemiol & Canc Prevent, Warsaw - Poland
[13] M Sklodowska Curie Inst Oncol, Warsaw - Poland
[14] Hosp Clin Porto, Oncol Unit, Porto Alegre, RS - Brazil
[15] Univ Fed Pelotas, Sch Med, Dept Internal Med, Pelotas - Brazil
[16] Charles Univ Prague, Gen Univ Hosp, Prague - Czech Republic
[17] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague - Czech Republic
[18] Inst Hyg Publ Hlth Hlth Serv & Management, Bucharest - Romania
[19] Inst Nacl Oncol & Radiobiol, Havana - Cuba
[20] Specialized Inst Hyg & Epidemiol, Banska Bystrica - Slovakia
[21] Int Prevent Res Inst, F-69006 Lyon - France
[22] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY 10029 - USA
Total Affiliations: 22
|
| Document type: | Journal article |
| Source: | International Journal of Epidemiology; v. 40, n. 2, p. 489-502, APR 2011. |
| Web of Science Citations: | 100 |
| Abstract | |
Background Recent studies support an important role for human papillomavirus (HPV) in a subgroup of head and neck squamous cell carcinomas (HNSCC). We have evaluated the HPV deoxyribonucleic acid (DNA) prevalence as well as the association between serological response to HPV infection and HNSCC in two distinct populations from Central Europe (CE) and Latin America (LA). Methods Cases (n = 2214) and controls (n = 3319) were recruited from 1998 to 2003, using a similar protocol including questionnaire and blood sample collection. Tumour DNA from 196 fresh tissue biopsies was analysed for multiple HPV types followed by an HPV type-specific polymerase chain reaction (PCR) protocol towards the E7 gene from HPV 16. Using multiplex serology, serum samples were analysed for antibodies to 17 HPV types. Statistical analysis included the estimation of adjusted odds ratios (ORs) and the respective 95% confidence intervals (CIs). Results HPV16 E7 DNA prevalence among cases was 3.1% (6/196), including 4.4% in the oropharynx (3/68), 3.8% in the hypopharynx/larynx (3/78) and 0% among 50 cases of oral cavity carcinomas. Positivity for both HPV16 E6 and E7 antibodies was associated with a very high risk of oropharyngeal cancer (OR = 179, 95% CI 35.8-899) and hypopharyngeal/laryngeal cancer (OR = 14.9, 95% CI 2.92-76.1). Conclusions A very low prevalence of HPV DNA and serum antibodies was observed among cases in both CE and LA. The proportion of head and neck cancer caused by HPV may vary substantially between different geographical regions and studies that are designed to evaluate the impact of HPV vaccination on HNSCC need to consider this heterogeneity. (AU) | |